Study of BL-M07D1 vs chemo for HER2-low breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- Your breast cancer is HER2-low and has come back or spread and cannot be removed by surgery.
- You have not had previous treatment with anti-HER2 drugs or certain other targeted therapies.
- You can provide a recent tumor sample for testing.
- Your overall health is good (ECOG score 0 or 1) and your organs are working well.
- You are not pregnant and agree to use effective birth control during the study and for 7 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that has spread. The goal is to see if BL-M07D1 works better than standard chemo.
Hear when a new HER2-low Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.